Aromatase Inhibitor Host Factors Study

NACompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Breast Neoplasms
Interventions
DRUG

Letrozole

Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.

Trial Locations (3)

M5G 1M9

Princess Margaret Hospital, Toronto

M5G 1X5

Mount Sinai Hospital, Toronto

M5S 1B1

Women's College Hospital, Toronto

All Listed Sponsors
lead

Samuel Lunenfeld Research Institute, Mount Sinai Hospital

OTHER

NCT01669343 - Aromatase Inhibitor Host Factors Study | Biotech Hunter | Biotech Hunter